Press Releases

DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM

VANCOUVER, British Columbia and MENLO PARK, Calif., June 26, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today updated patient enrollment data for its Phase 2 open-label clinical trial of VAL-083 in bevacizumab (Avastin®)-naïve  recurrent glioblastoma multiforme (rGBM) patients with MGMT-unmethylated status.

This trial is being conducted at MD Anderson Cancer Center and as of June 15, 2018, has enrolled 33 of the planned 48 patients. The trial is designed to determine the impact of VAL-083 treatment on overall survival compared to historical reference control.

"We are pleased with the accelerated patient enrollment of our ongoing VAL-083 Phase 2 trial at MD Anderson Cancer Center. Presently, the trial is approximately six months ahead of schedule and based on the trial's protocol design, we anticipate the primary endpoint of median overall survival to be reached approximately three months after the final patient is enrolled," said Saiid Zarrabian, President and Chief Executive Officer of DelMar.

About VAL-083

VAL-083 (dianhydrogalactitol) is a "first-in-class," DNA-targeting agent that introduces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. VAL-083 has demonstrated clinical activity against a range of cancers including GBM and ovarian cancer in historical clinical trials sponsored by the U.S. National Cancer Institute ("NCI").  DelMar has demonstrated that VAL-083's anti-tumor activity is unaffected by common mechanisms of chemoresistance in vitro. Further details regarding these studies can be found at: 

http://www.delmarpharma.com/scientific-publications.html.

VAL-083 has been granted an orphan drug designation by the U.S. FDA Office of Orphan Products for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant gliomas.  VAL-083 has been granted fast-track status for the treatment of recurrent GBM by the US FDA.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options.  By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing, or unable to tolerate, standard of care treatments.

The Company's current pipeline is based around VAL-083, a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI).  Based on DelMar's internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 across multiple oncology indications to solve significant unmet medical needs.

VAL-083 is also being studied in two collaborator-supported, biomarker-driven, Phase 2 clinical trials for MGMT-unmethylated glioblastoma multiforme (GBM). Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM.  Further information on DelMar's clinical trials can be found on clinicaltrials.gov:

https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

Connect with the Company on TwitterLinkedInFacebook, and Google+.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks related to overall enrollment in the Phase 2 trial in MGMT-unmethylated Recurrent GBM, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Annual Report on Form 10-K for the year ended June 30, 2017, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K.

 

DelMar Pharmaceuticals Logo

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-announces-accelerated-patient-enrollment-of-phase-2-trial-in-mgmt-unmethylated-recurrent-gbm-300671281.html

SOURCE DelMar Pharmaceuticals, Inc.